124 related articles for article (PubMed ID: 12163838)
1. Alosetron (lotronex) revisited.
Med Lett Drugs Ther; 2002 Aug; 44(1136):67-8. PubMed ID: 12163838
[No Abstract] [Full Text] [Related]
2. Alosetron (Lotronex) for treatment of irritable bowel syndrome.
Med Lett Drugs Ther; 2000 Jun; 42(1081):53-4. PubMed ID: 10872030
[No Abstract] [Full Text] [Related]
3. Glaxo Wellcome withdraws irritable bowel syndrome medication.
FDA Consum; 2001; 35(1):3. PubMed ID: 11930921
[No Abstract] [Full Text] [Related]
4. FDA advisory panels recommend Lotronex be put back on market.
Charatan F
BMJ; 2002 May; 324(7345):1053. PubMed ID: 11993482
[No Abstract] [Full Text] [Related]
5. Incidence of colonic ischemia, hospitalized complications of constipation, and bowel surgery in relation to use of alosetron hydrochloride.
Miller DP; Alfredson T; Cook SF; Sands BE; Walker AM
Am J Gastroenterol; 2003 May; 98(5):1117-22. PubMed ID: 12809837
[TBL] [Abstract][Full Text] [Related]
6. Alosetron: ischemic colitis and serious complications of constipation.
Gallo-Torres H; Brinker A; Avigan M
Am J Gastroenterol; 2006 May; 101(5):1080-3. PubMed ID: 16696787
[TBL] [Abstract][Full Text] [Related]
7. FDA draws patients into alosetron risk management.
Miller JL
Am J Health Syst Pharm; 2000 Oct; 57(19):1736. PubMed ID: 11030021
[No Abstract] [Full Text] [Related]
8. Lotronex(tm): therapy for diarrhea predominant irritable bowel syndrome.
McGahan L
Issues Emerg Health Technol; 2000 Oct; (11):1-5. PubMed ID: 11902219
[No Abstract] [Full Text] [Related]
9. Alosetron in irritable bowel syndrome.
McColl KE
Lancet; 2000 Jul; 356(9224):164-5. PubMed ID: 10963271
[No Abstract] [Full Text] [Related]
10. Re: Brandt et al.--An evidence-based approach to the management of irritable bowel syndrome in North America.
Avigan M; Justice R; Mackey AC; Nair N
Am J Gastroenterol; 2003 Sep; 98(9):2105-6. PubMed ID: 14499800
[No Abstract] [Full Text] [Related]
11. Alosetron (Lotronex) is back: should I use it to treat my patients with irritable bowel syndrome?
Shen B; Soffer EE
Cleve Clin J Med; 2003 Jan; 70(1):64-5. PubMed ID: 12549728
[No Abstract] [Full Text] [Related]
12. Lotronex withdrawal.
Lisi DM
Arch Intern Med; 2002 Jan; 162(1):101. PubMed ID: 11784233
[No Abstract] [Full Text] [Related]
13. Innovative treatments for irritable bowel syndrome featured in new continuing ed program.
Rep Med Guidel Outcomes Res; 2000 Jul; 11(14):1-2, 5-6. PubMed ID: 11771560
[No Abstract] [Full Text] [Related]
14. Lotronex withdrawn from market.
Harv Womens Health Watch; 2001 Feb; 8(6):6. PubMed ID: 11175468
[No Abstract] [Full Text] [Related]
15. Irritable bowel syndrome. New treatment drug on the market.
Harv Health Lett; 2000 Jun; 25(8):7. PubMed ID: 10810051
[No Abstract] [Full Text] [Related]
16. Return of alosetron.
Hyman PE; Garvey TQ
Expert Opin Drug Saf; 2002 May; 1(1):1-4. PubMed ID: 12904154
[No Abstract] [Full Text] [Related]
17. Alosetron.
Balfour JA; Goa KL; Perry CM
Drugs; 2000 Mar; 59(3):511-8; discussion 519-20. PubMed ID: 10776833
[TBL] [Abstract][Full Text] [Related]
18. Safety concerns about alosetron.
Camilleri M
Arch Intern Med; 2002 Jan; 162(1):100-1. PubMed ID: 11784232
[No Abstract] [Full Text] [Related]
19. So what happened to alosetron?
Hyams JS
J Pediatr Gastroenterol Nutr; 2001 May; 32(5):513-4. PubMed ID: 11455947
[No Abstract] [Full Text] [Related]
20. Alosetron for irritable bowel syndrome. Risks of using alosetron are still unknown.
Palmer RH
BMJ; 2003 Jan; 326(7379):51. PubMed ID: 12518769
[No Abstract] [Full Text] [Related]
[Next] [New Search]
